Marc Began - 04 Nov 2022 Form 4 Insider Report for ABIOMED INC (NASD)

Role
VP & GENERAL COUNSEL
Signature
/s/ Michael Dube (by power of attorney)
Issuer symbol
NASD
Transactions as of
04 Nov 2022
Transactions value $
-$1,326,357
Form type
4
Filing time
08 Nov 2022, 15:34:22 UTC
Previous filing
30 Aug 2022
Next filing
27 Dec 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NASD Common Stock, $0.01 par value Sale -$747K -2K -12.67% $373.71* 13.8K 04 Nov 2022 Direct F1, F2
transaction NASD Common Stock, $0.01 par value Tax liability -$579K -1.55K -11.23% $373.99* 12.2K 05 Nov 2022 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding NASD Stock Option (Right to Buy) 7K 04 Nov 2022 Common Stock 0 $266.39 Direct F4, F5
holding NASD Stock Option (Right to Buy) 5.13K 04 Nov 2022 Common Stock 0 $223.90 Direct F4, F5
holding NASD Stock Option (Right to Buy) 2.96K 04 Nov 2022 Common Stock 0 $283.88 Direct F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Sale of common stock pursuant to reporting owner's 10b5-1 plan.
F2 This price represents the sale price of the transactions on the reported date at $373.7100. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.
F3 Transaction represents shares of common stock withheld solely for the payment of withholding tax liability associated with the vesting of awards of restricted stock units in accordance with the time periods set forth in such awards.
F4 Grant to reporting person of option to buy the number of shares of Common Stock set forth in Table II, Column 7, under the ABIOMED, Inc. 2015 Omnibus Incentive Plan.
F5 These options become exercisable in annual 33-1/3% increments, commencing on the date shown in Table II, Column 6.